Premium
Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2)
Author(s) -
Kaplan Mark J.,
Somers Robert G.,
Greenberg Richard H.,
Ackler Joann
Publication year - 1998
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199802)67:2<121::aid-jso9>3.0.co;2-c
Subject(s) - medicine , photodynamic therapy , adenocarcinoma , surgery , biopsy , metastatic breast cancer , metastatic adenocarcinoma , radiology , oncology , cancer , breast cancer , chemistry , organic chemistry
Background and Objectives: Photodynamic therapy (PDT) using a photoreactive purpurin, tin ethyl etiopurpurin (SnET2, Purlytin⌖, Miravant Medical Technologies, Santa Barbara, CA), was investigated as a treatment for cutaneous metastatic disease that had failed other treatment options. Study Design/Materials and Methods: Three patients with biopsy‐proven metastatic adenocarcinoma of the skin were treated with a single dose of the study drug. Twenty‐four hours later, the patients were exposed to a laser light at 664 nm in multiple light fields. Patients were followed for 6 months for safety, efficacy, recurrence, and palliative response. Results After PDT with SnET2, complete response was observed in all 13 treated lesions in three patients, with no evidence of recurrence at any treated site at the 6‐month follow‐up. Two patients subsequently died of distant metastatic disease. One patient with local chest wall recurrence after mastectomy was disease‐free 24 months after PDT. Conclusions PDT with SnET2 could be an effective treatment in locally advanced metastatic carcinoma of the skin. J. Surg. Oncol. 1998:67:121–125. © 1998 Wiley‐Liss, Inc.